ArticleTranslational cancer research2026
A novel gene signature based on Like-Smith family members-related genes for predicting the prognosis of hepatocellular carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths globally. The Like-Smith (LSM) family members are involved in RNA metabolism and tumor progression, but their role in HCC remains unclear. This study aims to construct a novel signature based on LSM family members-related genes and explore its clinical value in HCC. Methods: Molecular patterns related to LSM family members were identified through clustering analysis. Differential expression analysis was used to identify genes with potential prognostic significance. Multivariate Cox regression analysis was performed to construct a signature with The Cancer Genome Atlas (TCGA) cohort. The International Cancer Genome Consortium (ICGC) cohort served as external validation. Kaplan-Meier curves and receiver operating characteristic (ROC) curves were used to evaluate the predictive ability. Enrichment analysis, immune infiltration assessment, and single-cell RNA sequencing (scRNA-seq) data analysis were conducted to explore the underlying mechanisms. Results: Two genes-paired-like homeodomain 2 ( Conclusions: The novel two-gene signature comprising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.